ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO357

V1a Receptor-Mediated Kidney Tissue Oxygenation Is Independent of Vasopressin V2 Receptor Blockade

Session Information

  • CKD: Mechanisms - II
    November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2103 CKD (Non-Dialysis): Mechanisms

Authors

  • Cernecka, Hana, Bayer AG, Wuppertal, Germany
  • Droebner, Karoline, Bayer AG, Wuppertal, Germany
  • Mondritzki, Thomas, Bayer AG, Wuppertal, Germany
  • Collin, Marie-Pierre Laure, Bayer AG, Wuppertal, Germany
  • Eitner, Frank, Bayer AG, Wuppertal, Germany
  • Kolkhof, Peter, Bayer AG, Wuppertal, Germany
Background

AVP binds to two subtypes of receptors in the kidney, the V1a and V2 receptors mediating different cellular effects. Selective V2 receptor antagonism induces aquaresis and is an efficacious decongestive approach. We showed that selective V1a receptor inhibition improves kidney oxygenation and kidney function which might be relevant for conditions of increased AVP levels such as chronic kidney disease. We investigated the potential interference of selective V2 antagonism with V1a antagonism on kidney oxygenation.

Methods

The effects of selective V2 antagonism (tolvaptan or satavaptan), selective V1a antagonism (relcovaptan) or a combination of both on renal blood flow (RBF) and tissue oxygenation (pO2) were investigated in isolated perfused rat kidneys (IPK) and in anesthetized Sprague Dawley rats (n=7 per group) via Laser Doppler Flowmetry in settings of increased AVP levels.

Results

Tolvaptan (0.3–100 nM) had no effect on the AVP-mediated (50 nM) reduction of perfusate flow while increasing urine excretion (p=0.07). In vivo, infusion of AVP (50 ng/kg/min i.v.) significantly increased mean arterial pressure (MAP) and reduced both RBF and tissue pO2 (Table 1). Dose-dependent infusion of tolvaptan did not reduce the increased MAP values and did neither restore RBF nor kidney pO2 levels. Similar results were achieved with satavaptan. Combination of V1a antagonism (relcovaptan) with V2 antagonism (tolvaptan) normalized AVP-increased MAP and restored RBF and pO2 back to basal values similar to the individual V1a antagonism (Table 1).

Conclusion

Selective V2 inhibition has no impact on renal oxygenation in settings of increased AVP levels and does not interfere with V1a receptor blockade-mediated beneficial effects on kidney oxygenation. Therefore, addressing the individual vasopressin receptors alone or in combination in cardiorenal diseases is dependent on the presence of congestion and/or kidney hypoxia.

*/**** p<0.05/0.0001 vs. AVP (One-way ANOVA)
#/##/#### p<0.05/0.01/0.0001 vs. AVP (t test)

Funding

  • Commercial Support